 8. Patients on the following medication will be excluded: a. Anticonvulsants: Patients on Enzyme Inducing Anticonvulsants EIAED will be excluded. If patients were previously on EIAEDs that have been discontinued, patients must have been off EIAEDs for 2 weeks prior to initiation of dasatinib. b. AnticoagulantsAnti-platelets: Patients on therapeutic treatment dose of anticoagulants e.g. warfarin, low molecular-weight heparin are not eligible. Patients are not allowed to take aspirin, clopidogrel, ticlopidine, Aggrenox. Patients on prophylactic anticoagulation may be enrolled and treated on study as long as their platelet count is monitored closely and maintained at 75,000 while they are receiving Dasatinib. 